Published in Genes Chromosomes Cancer on July 01, 1995
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol (1998) 1.51
Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol (2000) 1.21
Histopathology and molecular genetics of multiple cysts and microcystic (serous) adenomas of the pancreas in von Hippel-Lindau patients. Am J Pathol (2000) 1.15
A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest (1997) 1.03
Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol (1997) 1.01
Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. Br J Cancer (1998) 0.80
Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer (2008) 0.78
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol (1968) 3.62
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (1987) 3.46
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol (1999) 3.14
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92
Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat (1995) 2.91
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
Clinical forms of gonococcal arthritis. N Engl J Med (1968) 2.58
A Millipore filter assay for antibodies to native DNA in sera of patients with systemic lupus erythematosus. Arthritis Rheum (1973) 2.53
Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet (1994) 2.52
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med (2001) 2.45
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA (1995) 2.43
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04
Identification of an actin binding region and a protein kinase C phosphorylation site on human fascin. J Biol Chem (1997) 2.02
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res (1995) 1.91
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab (2001) 1.91
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
Hereditary papillary renal cell carcinoma. J Urol (1994) 1.87
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst (1974) 1.82
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene (1995) 1.82
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab (2000) 1.80
Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science (1971) 1.80
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Degradation of cartilage proteoglycan by human leukocyte granule neutral proteases--a model of joint injury. II. Degradation of isolated bovine nasal cartilage proteoglycan. J Clin Invest (1976) 1.77
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst (1972) 1.75
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst (1974) 1.74
Immunochemistry of cartilage proteoglycan. Immunodiffusion and gel-electrophoretic studies. Biochem J (1972) 1.67
BCG and cancer. N Engl J Med (1974) 1.66
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A (1996) 1.66
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med (1999) 1.65
Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med (1993) 1.65
Evaluation of the initial care of hypertensive patients. JAMA (1971) 1.64
Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am (2006) 1.64
Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science (1970) 1.64
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol (1996) 1.64
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A (1995) 1.61
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.59
Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol (2001) 1.58
Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci U S A (1992) 1.56
Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res (1992) 1.52
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52